![]() |
Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma
Panarat Orachum, Amornrat Temtanakitpaisan, Pilaiwan Kleebkaow, Bandit Chumworathayi, Sanguanchoke Luanratanakorn, Apiwat Aue-angkul, Yuwadee Itarat
Obstet Gynecol Sci. 2022;65(5):459-467. Published online 2022 Jul 29 DOI: https://doi.org/10.5468/ogs.22102
|
Citations to this article as recorded by
A line in shifting sand: Can we define and target TP53 mutated MDS?
Sarah Skuli, Andrew Matthews, Martin Carroll, Catherine Lai
Seminars in Hematology.2024; 61(6): 449. CrossRef TP53 in AML and MDS: The new (old) kid on the block
Jennifer A. Marks, Xin Wang, Elena M. Fenu, Adam Bagg, Catherine Lai
Blood Reviews.2023; 60: 101055. CrossRef
|